Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 11, 2019 - Issue
Submit an article Journal homepage
115
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis

Jennie H Best1 Genentech, Inc., South San Francisco, CA, USACorrespondence[email protected]
,
Amanda M Kong2 IBM Watson Health, Cambridge, MA, USAORCID Iconhttps://orcid.org/0000-0002-6210-4185
ORCID Icon,
David M Smith2 IBM Watson Health, Cambridge, MA, USA
,
Ibrahim Abbass1 Genentech, Inc., South San Francisco, CA, USA
&
Margaret Michalska1 Genentech, Inc., South San Francisco, CA, USA
Pages 799-807 | Published online: 23 Dec 2019

References

  • Pfeil A, Oelzner P, Hellmann P. The treatment of giant cell arteritis in different clinical settings. Front Immunol. 2019;9:3129. doi:10.3389/fimmu.2018.0312930733723
  • Ness T, Bley TA, Schmidt WA, Lamprecht P. The diagnosis and treatment of giant cell arteritis. Dtsch Arztebl Int. 2013;110(21):376–385. doi:10.3238/arztebl.2013.037623795218
  • Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79(5):283–292. doi:10.1097/00005792-200009000-0000111039076
  • Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347(4):261–271. doi:10.1056/NEJMra01191312140303
  • Nesher G, Breuer GS. Giant cell arteritis and polymyalgia rheumatica: 2016 update. Rambam Maimonides Med J. 2016;7(4):e0035. doi:10.5041/RMMJ.20769172
  • Kermani TA, Schafer VS, Crowson CS, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis. 2010;69(4):780–781. doi:10.1136/ard.2009.11100519854712
  • Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35. doi:10.1002/art.2317618163497
  • Fraser JA, Weyand CM, Newman NJ, Biousse V. The treatment of giant cell arteritis. Rev Neuro Dis. 2008;5(3):140–152.
  • Broder MS, Sarsour K, Chang E, et al. Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin Arthritis Rheum. 2016;46(2):246–252. doi:10.1016/j.semarthrit.2016.05.00927378247
  • Kotter I, Henes JC, Wagner AD, Loock J, Gross WL. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S114–S129.22640655
  • Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703–708. doi:10.1002/(ISSN)1529-013114558057
  • Gale S, Wilson JC, Chia J, et al. Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK. Rheumatol Ther. 2018;5(2):1–14.29480358
  • Lai LYH, Harris E, West RM, Mackie SL. Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis. RMD Open. 2018;4(1):e000521. doi:10.1136/rmdopen-2017-00052129531778
  • Wilson JC, Sarsour K, Collinson N, et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis. Semin Arthritis Rheum. 2017;46(6):819–827. doi:10.1016/j.semarthrit.2016.11.00628040244
  • Best JH, Kong AM, Lenhart GM, Sarsour K, Stott-Miller M, Hwang Y. Association between glucocorticoid exposure and healthcare expenditures for potential glucocorticoid-related adverse events in patients with rheumatoid arthritis. J Rheumatol. 2018;45(3):320–328. doi:10.3899/jrheum.17041829335343
  • Babigumira JB, Li M, Boudreau DM, Best JH, Garrison LP. Estimating the cost of illness of giant cell arteritis in the United States. Rheumatol Ther. 2017;4(1):111–119. doi:10.1007/s40744-017-0052-828084585
  • Cotch MF. The socioeconomic impact of vasculitis. Curr Opin Rheumatol. 2000;12(1):20–23. doi:10.1097/00002281-200001000-0000410647950
  • De Smit E, Palmer AJ, Hewitt AW. Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol. 2015;42(1):119–125. doi:10.3899/jrheum.14031825362658
  • Chandran A, Udayakumar PD, Kermani TA, Warrington KJ, Crowson CS, Matteson EL. Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Clin Exp Rheumatol. 2015;33(2 Suppl 89):S98–S102.
  • Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol. 1994;21(7):1283–1286.7966070
  • Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328. doi:10.1056/NEJMoa161384928745999

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.